1
1
2
2
3
3
2
2
1
1
2017
2008
Company (9)University (5)
1 - 9 of 9
Sort by
Patent
Publication NumberEP 2726635 B1Filing StatusIssued PatentAvailabilityUnknownFiling Date2012-06-29Publication Date2017-11-08
Patent
Publication NumberUS 9476098Filing StatusIssued PatentAvailabilityUnknownFiling Date2012-06-29Publication Date2016-10-25
The present invention provides methods for providing a prognosis for lung cancer using a panel of eleven molecular markers that includes BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, and WNT3A, which are differentially expressed in lung cancer. The eleven markers are related to patient prognosis to 5-year overall survival outcomes, and are particularly useful in providing a prognosis for non-squamous NSCLC.
Patent
Publication NumberAU 2012279173 B2Filing StatusIssued PatentAvailabilityUnknownFiling Date2012-06-29Publication Date2016-06-16
The present invention provides methods for providing a prognosis for lung cancer using a panel of eleven molecular markers that includes BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, and WNT3A, which are differentially expressed in lung cancer. The eleven markers are related to patient prognosis to 5 -year overall survival outcomes, and are particularly useful in providing a prognosis for non-squamous NSCLC.
Patent
Publication NumberCN 103998622 AFiling StatusPatent ApplicationAvailabilityUnknownFiling Date2012-06-29Publication Date2014-08-20
The present invention provides methods for providing a prognosis for lung cancer using a panel of eleven molecular markers that includes BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, and WNT3A, which are differentially expressed in lung cancer. The eleven markers are related to patient prognosis to 5 -year overall survival outcomes, and are particularly useful in providing a prognosis for non-squamous NSCLC.
Patent
Publication NumberUS 20140147855Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2012-06-29Publication Date2014-05-29
The present invention provides methods for extracting RNA from formalin fixed embedded tissue wherein the extracted RNA provides reliable results in assays for RNA quantity such as PCR assays.
Patent
Publication NumberEP 2726609 A1Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2012-06-29Publication Date2014-05-07
Patent
Publication NumberWO 2013006502 A1Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2012-06-29Publication Date2013-01-10
The present invention provides methods for extracting RNA from formalin fixed embedded tissue wherein the extracted RNA provides reliable results in assays for RNA quantity such as PCR assays. The methods comprise the steps of removing the embedding material; incubating the tissue with a protease; removing protein from nucleic acids; precipitating nucleic acids; removing DNA from the nucleic acids; and purifying the RNA by binding to and eluting from a silica gel membrane.
Patent
Publication NumberWO 2013006503 A1Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2012-06-29Publication Date2013-01-10
The present invention provides methods for providing a prognosis for lung cancer using a panel of eleven molecular markers that includes BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, and WNT3A, which are differentially expressed in lung cancer. The eleven markers are related to patient prognosis to 5 -year overall survival outcomes, and are particularly useful in providing a prognosis for non-squamous NSCLC.
SEC Filing
Accession Number9999999997-08-036300Form TypeREGDEXAcceptance Date2008-08-20
This document was generated as part of a paper submission.Please reference the Document Control Number 08057987 for access to the original document.
We found 9 documents that match your Search
Patents: 8
SEC Filings: 1

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in